Asset Quality Surges; Revenue Growth Stalls

Fusion's Q1 FY27 quarter is a tale of two readings. On asset quality, the story is straightforward and positive: GNPA fell 70 basis points to 2.51%, credit cost declined for the seventh consecutive quarter to ₹40 crore, and collection efficiency held steady at 99.75% or better. The portfolio deleveraging cycle has clearly bottomed, and management's guardrail discipline (relaxing Fusion+2 selectively after testing new customer cohorts) is validating early: 42% of July disbursements were new-to-Fusion customers, and they're repaying impeccably. On that read alone, Fusion deserves credit for operational excellence in a complex market.

But the revenue story tells a different tale. Despite disbursement growth of 88% year-over-year to ₹1,783 crore and AUM expansion to ₹7,702 crore (4% quarter-on-quarter), reported revenue grew only 5.5% year-over-year to ₹458.2 crore. That gap—88% disbursement growth paired with 5.5% revenue growth—is the quarter's defining tension. It signals either mix shift to lower-yield products, new customer acquisition at compressed yields, or both. The company is banking on operating leverage (NIM expansion of 15–20 basis points by year-end, cost reductions via branch rationalization) to offset the revenue slowdown. That thesis is credible but unproven, and it's what separates the bulls from the sceptics.

The reported PAT of ₹62.4 crore looks even stronger on the 167.7% year-over-year growth rate, but context matters. The prior-year base (₹23.4 crore in Q1 FY26) was depressed by deleveraging provision hits. Stripping out ₹4 crore in mark-to-market impact on finance costs and ₹3.5–4 crore in drag from excess liquidity holdings, the normalized run-rate sits in the ₹55–60 crore band. The quarter-on-quarter decline of 45.3% from Q4's ₹114.2 crore is partly seasonal—Q4 was abnormally high—but the magnitude signals structural headwinds that management hasn't fully neutralized yet. Earnings quality, then, depends on whether operating leverage kicks in from Q2 onwards.

Four operational moves signal a shift in execution confidence post-West Asia crisis:

Credit recovery is real and durable. Seven consecutive quarters of credit cost decline; GNPA trending down (2.51%, −70 bps quarter-on-quarter); collection efficiency 99.75%+ held across all geographies (rain-fed, heat-stressed states) and delinquency buckets. New-to-Fusion customers (37–42% of disbursements) are showing pristine repayment despite guardrail relaxation. This validates the PQM (Portfolio Quality Management) credit model and management's discipline.

AUM target is on track and achievable. ₹10,000 crore by March 2027 requires 29.6% growth over 9 months from a ₹7,702 crore base. Currently 77% achieved; H1 disbursement at 45% of annual run-rate is pacing the goal. Individual loans (Sep launch) and MSME 200-branch rollout are growth levers that don't need to carry heavy weight in H1 (45% of disbursement already targeted from MFI core).

NIM expansion thesis is credible. 55 basis points in customer yield increases are partially baked in (12 bps so far); the remaining ~25–30 bps will flow as new disbursements reprice and legacy book rolls. Management's 15–20 basis points guidance by year-end is conservative; the range could extend to 25 bps if cost-of-funds decline and yield realization hold. This offsets revenue growth slowdown if executed.

Operating leverage is within reach. OpEx budgeted for 4–5% growth despite 20–25% AUM CAGR targets via branch rationalization (closing 100 underperforming branches, opening 50 high-potential ones; net closure of 40–50). Long-term target: 6–7% opex-to-average-AUM vs current levels.

Revenue growth dramatically lags operational metrics. Disbursement growth of 88% year-over-year paired with AUM growth of 4% quarter-on-quarter should drive revenue growth significantly higher than 5.5% year-over-year. The gap signals either mix shift to lower-yield products (MSME secured, individual loans launching Sep) or new customer acquisition at compressed initial yields (37–42% of disbursements). If this trend persists, margin expansion from NIM will struggle to offset revenue slowdown.

New product launches are unproven. Individual loans (₹1.5 lakh ticket, Sep 2026 first disbursement) and MSME scaling (200-branch rollout, target 15% of AUM) are material growth levers, but execution risk is material. First-quarter contribution to the portfolio is unknown; collection efficiency (MSME 99.3%+, individual loans untested) may underperform legacy MFI (99.75%+). If credit quality deteriorates or credit costs spike in new products, the portfolio-quality narrative breaks.

AUM target is aggressive despite pacing. 29.6% growth in 9 months (to hit ₹10,000 crore by March 2027) requires sustained approval rates, tight guardrails, and new product contribution. If monsoon stress hits Q2–Q3 or market competition intensifies, approval rates could soften and the target could slip.

Quarter-on-quarter profit cliff signals structural headwinds. PAT of ₹62.4 crore in Q1 fell 45.3% from Q4's ₹114.2 crore despite better asset quality. Management attributes this to seasonal normalization and Q4 abnormality, but the magnitude raises questions about cost structure, tax rates, or funding costs that have tightened.

The market's initial reaction was cautiously constructive: the stock popped 2.89% on day 1 of result disclosure (announced 11:48 AM on Monday, 10 Aug 2026 with a pre-result close of ₹206.16), but the move faded to −0.76% by day 3. That fade—only 76 basis points from the pop—suggests the street viewed the quarter as in-line, not exceptional. The current price of ₹195.58 sits well below key moving averages (SMA20 ₹209.92, SMA50 ₹203.83) but above the 200-day average (₹181.29), indicating loss of momentum but no capitulation. The stock is down 19.51% from its all-time high of ₹243, yet up 43.28% off its 52-week low of ₹136.5—a wide range reflecting volatility from the deleveraging cycle recovery. RSI of 39.1 is neutral, and volume is increasing, suggesting some accumulation is building.

Institutional flows are marginally constructive. Foreign institutional investors added 3 basis points quarter-on-quarter to 4.77%, domestic institutional investors added 83 basis points to 15.25%, and the promoter trimmed 15 basis points to 54.15%. The FII and DII moves are small, but the direction (adding) suggests cautious confidence in the business recovery. Promoter trimming is benign at this scale (−15 bps) and could reflect routine rebalancing rather than conviction selling. The street's read: credible asset-quality recovery, but revenue concerns warrant a wait-and-see posture on valuation.

Organic revenue growth rate (ex new products, ex one-time items) by Q2 FY27. If it re-accelerates to 8–10% year-over-year, the margin-expansion and operating-leverage thesis gains credibility and the stock has re-rating upside. If it stays flat at 5–6% despite AUM scaling, yield compression is structural and the stock will struggle to appreciate materially even if profitability grows via cost cuts. This one metric determines whether Fusion is a steady compounder (Hold) or a portfolio recovery play with limited upside (Avoid).